Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dynactin associated protein pseudogene 2 (DYNAPP2) is annotated as a pseudogene, meaning it bears sequence similarity to "dynactin associated protein" genes but is considered nonfunctional due to disruptive mutations in its sequence[1][2][4]. In general, pseudogenes were long viewed as nonfunctional relics of evolution but are now known in some cases to participate in regulation of gene expression through mechanisms such as acting as decoys for microRNAs (competing endogenous RNAs, or ceRNAs) or potentially producing regulatory non-coding RNAs[2][3]. However, there is no evidence that DYNAPP2 itself is expressed or functional, or that it encodes a protein, or acts as a receptor, enzyme, or any other classical therapeutic target. There is no data reporting DYNAPP2 as a biomarker, safety concern, or drug target. Pseudogenes in general may have context-dependent regulatory effects, but unless explicitly supported by experimental evidence (which does not exist for DYNAPP2), DYNAPP2 should be considered a nonfunctional genomic element with no established protein product or therapeutic relevance[2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dynactin associated protein pseudogene 2 (DYNAPP2).